We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Experimental Drug Blocks Development of Malignant Melanomas

By LabMedica International staff writers
Posted on 14 Feb 2019
Print article
Image: The structure of the NRAS protein (Photo courtesy of Wikimedia Commons).
Image: The structure of the NRAS protein (Photo courtesy of Wikimedia Commons).
A promising experimental drug may prevent growth and spread of malignant melanomas having a mutation in the NRAS gene.

Activating mutations in the NRAS (Neuroblastoma RAS viral oncogene homolog) gene account for 20%–30% of melanoma, but despite decades of research no effective anti-NRAS therapies have been developed.

With this in mind, investigators at Boston University School of Medicine (MA, USA) identified the previously uncharacterized serine/threonine kinase STK19 as a novel NRAS activator. The protein encoded by STK19 localizes predominantly to the nucleus. Its specific function is unknown, but it is thought that phosphorylation of this protein may be involved in transcriptional regulation.

The investigators reported in the January 31, 2019, online edition of the journal Cell that STK19 phosphorylated NRAS, which enhanced its binding to its downstream effectors and promoted oncogenic NRAS-mediated melanocyte malignant transformation. A recurrent D89N (aspartate (D89) to aspargine) substitution in STK19 - whose alterations were identified in 25% of human melanomas - represented a gain-of-function mutation that interacted better with NRAS to enhance melanocyte transformation. STK19 D89N activation led to skin hyperpigmentation and promoted NRAS-driven melanoma formation in vivo.

In addition, the investigators described the development of the drug ZT-12-037-01 as a specific STK19-targeted inhibitor and showed that it effectively blocked oncogenic NRAS-driven melanocyte malignant transformation and melanoma growth in vitro and in vivo.

"This study provides a promising therapeutic strategy for melanoma treatment. Furthermore, the STK19 inhibitor might be a therapeutic option in 25% of all cancers with RAS mutations," said senior author Dr. Rutao Cui, professor of pharmacology and experimental therapeutics at Boston University School of Medicine. "We hope our findings ultimately will be clinically translated into improved care for cancer patients."

Related Links:
Boston University School of Medicine

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Cancer Mutation Profiling Liquid Kit
OncoScreen Plus

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.